{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:28Z","timestamp":1791340348612,"version":"4.3.1"},"reference-count":91,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\n<jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Preclinical Research<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n<\/jats:table-wrap><\/jats:p><jats:p>The efficacy of anti\u2010TNF agents in the treatment of multiple immune\u2010mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long\u2010term safety profile. Using a literature\u2010based review of the infectious and malignant complications of anti\u2010TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti\u2010TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti\u2010TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating  the safety aspects and via a thorough screening and continuous monitoring of the patient. Drug Dev Res 76 : 419\u2013427, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ddr.21285","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T10:44:38Z","timestamp":1445337878000},"page":"419-427","source":"Crossref","is-referenced-by-count":54,"title":["Safety of Anti\u2010TNF Therapies in Immune\u2010Mediated Inflammatory Diseases: Focus on Infections and Malignancy"],"prefix":"10.1002","volume":"76","author":[{"given":"Rui","family":"Pereira","sequence":"first","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Centro Hospitalar do Porto  Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Lago","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Centro Hospitalar do Porto  Portugal"},{"name":"Department of Gastroenterology Centro Hospitalar do Porto  Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Centro Hospitalar do Porto  Portugal"},{"name":"Clinical Immunology Unit Centro Hospitalar do Porto  Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Centro Hospitalar do Porto  Portugal"},{"name":"Department of Dermatology Centro Hospitalar do Porto  Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"HUMIRA\u00ae (adalimumab) prescribing information","author":"AbbVie Inc.","year":"2014"},{"key":"e_1_2_5_3_1","first-page":"193","article-title":"Anti\u2010TNF therapy in Jordan: a focus on severe infections and tuberculosis","volume":"8","author":"Alawneh KM","year":"2014","journal-title":"Biologics"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2046"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.02.002"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203407"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"e_1_2_5_10_1","article-title":"The risk of post\u2010operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures","author":"Bakkour W","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21193"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301133"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-98"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000243"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.07.009"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21198"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"e_1_2_5_21_1","first-page":"269","article-title":"Infectious complications of TNF\u2010\u03b1 inhibitor monotherapy versus Combination therapy with immunomodulators in inflammatory bowel disease: analysis of the food and Drug Administration Adverse Event Reporting System","volume":"22","author":"Deepak P","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21189"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354703"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.138"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.098822"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201108"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798157658"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-77"},{"key":"e_1_2_5_32_1","first-page":"1035","article-title":"Clinical use of anti\u2010TNF\u2010alpha biological agents: a guide for GPs","volume":"36","author":"Girgis L","year":"2007","journal-title":"Aust Fam Physician."},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1692"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep325"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00898.x"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318280ebbd"},{"key":"e_1_2_5_37_1","volume-title":"ENBREL\u00ae (etanercept), prescribing information","author":"Immunex Corporation","year":"2013"},{"key":"e_1_2_5_38_1","volume-title":"REMICADE\u00ae (infliximab), prescribing information","author":"Janssen Biotech, Inc","year":"2013"},{"key":"e_1_2_5_39_1","volume-title":"SIMPONI\u00ae (golimumab), prescribing information","author":"Janssen Biotech, Inc.","year":"2013"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.05.012"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.12.024"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.034"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.suppl_2.ii34"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100995"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12744"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101009"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22954"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.052688"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318211106a"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-013-9481-5"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091025"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.004"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.006"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.322"},{"key":"e_1_2_5_56_1","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis D","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq368"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2014.881715"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048991"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.18.s2.2.x"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.630388"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12313"},{"key":"e_1_2_5_63_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.18433\/J3WP4F","article-title":"Safety of Anti\u2010Tumor Necrosis Factor Therapies in Arthritis Patients","volume":"17","author":"Neuman MG","year":"2014","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_2_5_64_1","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti\u2010TNF\u2010alpha treatment","volume":"59","author":"Nordgaard\u2010Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182380a76"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep423"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137422"},{"key":"e_1_2_5_69_1","first-page":"S10","article-title":"Why do anti\u2010tumor necrosis factor antibodies work in Crohn's disease?","volume":"4","author":"Sands BE.","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_5_70_1","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.4049\/jimmunol.157.11.5022","article-title":"Corynebacterium parvum\u2010 and Mycobacterium bovis bacillus Calmette\u2010Guerin\u2010induced granuloma formation is inhibited in TNF receptor I (TNF\u2010RI) knockout mice and by treatment with soluble TNF\u2010RI","volume":"157","author":"Senaldi G","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.67"},{"key":"e_1_2_5_72_1","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta\u2010analysis and Cochrane overview","volume":"16","author":"Singh JA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.464"},{"key":"e_1_2_5_76_1","first-page":"31","article-title":"Effects of infliximab treatment on rheumatoid synovial tissue","volume":"74","author":"Tak PP.","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit489"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_5_80_1","volume-title":"CIMZIA\u00ae (certolizumab pegol), prescribing information","author":"UCB","year":"2013"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0337-z"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127233"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2003.08.015"},{"key":"e_1_2_5_84_1","first-page":"S664","article-title":"Immune\u2010mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs","volume":"8","author":"Williams J","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.08.019"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1099"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133843"},{"key":"e_1_2_5_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20311"},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22579"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12060"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21285","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:43:51Z","timestamp":1760373831000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/ddr.21285"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21285","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}